Immunotherapies for Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 27847
Special Issue Editors
Interests: prostate cancer; diagnosis; oncology; statistic; R project for statistical computing; biomarker
Special Issues, Collections and Topics in MDPI journals
2. University of Montreal Hospital Research Centre, 900 Saint Denis St, Montreal, Quebec H2X 0A9, Canada
Interests: molecular oncology, prostate cancer, biomarker, therapy resistance, experimental therapy for advanced prostate cancer, translational research, novel research model, patient-derived xenograft (PDX), patient-derived organoids (PDO), microfluidics, lab-on-a-chip
Special Issue Information
Dear Colleagues,
Immunotherapy is the treatment of a disease by activating, enhancing, or suppressing an immune response. If the immune system recognizes the tumor cells as "bad", tumor cells can be fought using an immunological response, which has been an interesting research area for clinical treatment for years. What can we expect in the near future in immunological cancer therapy? Since the use of interferon (IFN alpha) for the treatment of patients with hairy cell leukemia or of interleukin-2 (IL-2) for the treatment of metastatic renal cell carcinoma, there have been further successful developments in this area. The vaccine Sipuleucel-T was developed for prostate carcinoma, the checkpoint inhibitor ipilimumab for the treatment of advanced melanoma and a checkpoint inhibitor that acts against the protein programmed cell death 1 (PD-1) or its ligand PD-1 ligand 1. (PD-L1). However, there are still some hurdles to be overcome to ensure that it can be used effectively and with as few side effects as possible. The efficiency of immunotherapies is difficult to assess because only a subgroup of patients reacts immunologically to immunotherapy. Difficulties also arise with solid tumors due to the accessibility (delivery barriers) compared to hematological tumors. In addition, some undesired immunological side effects (autoimmune side effects) are known that lead to an attack on healthy tissue. This is also due to the high dose required due to short half-lives and ineffective transport technologies to the target tissue. Some therapeutics are already being used in numerous clinical trials, but many have not yet been approved by the drug authorities. New approaches are, e.g., the development of patient-specific immunotherapies based on biomarker expression on cancer cells. However, this also includes the controlled, timed and targeted release of drugs in immunotherapy via nanoparticles. Novel transport technologies, such as nanoparticles, implants, scaffolds, biomaterial and cell-based platforms, are required. These transport technologies should protect the drug until it is transported to the target cells or activation of the drugs through responsive stimuli, such as pH, light or ultrasound, can be enabled. Are we on the way to successfully beating cancer through therapy with checkpoint inhibitors (PD-1/PD-L1, CTLA4), cytokines for lymphocyte promotion (interferons, interleukins, granulocyte-marcrophage colony-stimulationg factor), engineered T cell therapies ( chimeric antigen receptor T, T cell receptor T cells), antibodies against co-stimulatory receptors (CD28, tumor necrosis factor receptor family), cancer vaccines (tumor cell lysate, dendritic cells, nucleic acids, neo-antigens), oncolytic viruses or bispecific antibodies? Submit your current research results and share them with the research community. This is the only way to successfully offer individual and optimal cancer therapy for patients in the near future.
Dr. Pierre Tennstedt
Dr. Su Jung Oh-Hohenhorst
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
